Saniona AB (publ) Logo

Saniona AB (publ)

SANION.ST

(0.8)
Stock Price

4,79 SEK

-123.53% ROA

-1107.63% ROE

-1.8x PER

Market Cap.

211.772.783,00 SEK

0% DER

0% Yield

-568.94% NPM

Saniona AB (publ) Stock Analysis

Saniona AB (publ) Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Saniona AB (publ) Fundamental Stock Analysis
# Analysis Rating
1 Revenue Growth

With a track record of consistent revenue growth in the past five years, this company presents a compelling opportunity.

2 Net Profit Growth

Over the last three years, this company has consistently achieved net profit growth, indicating a favorable financial performance and making it an attractive investment option.

3 ROE

The stock's ROE indicates a negative return (-136.99%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-60.97%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 PBV

The stock's elevated P/BV ratio (24.65x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

6 DER

The stock is burdened with a heavy load of debt (431%), making it financially unstable and potentially risky for investors.

7 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

8 Graham Number

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

9 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (-2) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Saniona AB (publ) Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Saniona AB (publ) Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Saniona AB (publ) Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Saniona AB (publ) Revenue
Year Revenue Growth
2012 7.765.929
2013 13.640.754 43.07%
2014 21.718.000 37.19%
2015 13.630.000 -59.34%
2016 74.921.000 81.81%
2017 20.692.000 -262.08%
2018 54.884.000 62.3%
2019 2.658.000 -1964.86%
2020 8.198.000 67.58%
2021 10.478.000 21.76%
2022 15.283.000 31.44%
2023 21.804.000 29.91%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Saniona AB (publ) Research and Development Expenses
Year Research and Development Expenses Growth
2012 0
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Saniona AB (publ) General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 5.166.518
2013 5.110.818 -1.09%
2014 15.022.000 65.98%
2015 23.926.000 37.21%
2016 51.098.000 53.18%
2017 51.387.000 0.56%
2018 80.149.000 35.89%
2019 74.984.000 -6.89%
2020 97.107.000 22.78%
2021 239.267.000 59.41%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Saniona AB (publ) EBITDA
Year EBITDA Growth
2012 -2.184.059
2013 -1.240.595 -76.05%
2014 -6.969.000 82.2%
2015 -28.449.000 75.5%
2016 5.531.000 614.36%
2017 -55.338.000 109.99%
2018 -47.501.000 -16.5%
2019 -81.078.000 41.41%
2020 -162.004.000 49.95%
2021 -403.255.000 59.83%
2022 -217.779.000 -85.17%
2023 -60.576.000 -259.51%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Saniona AB (publ) Gross Profit
Year Gross Profit Growth
2012 6.710.243
2013 12.964.737 48.24%
2014 19.989.000 35.14%
2015 11.580.000 -72.62%
2016 73.445.000 84.23%
2017 17.429.000 -321.4%
2018 50.795.000 65.69%
2019 -859.000 6013.27%
2020 4.946.000 117.37%
2021 5.848.000 15.42%
2022 10.808.000 45.89%
2023 15.660.000 30.98%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Saniona AB (publ) Net Profit
Year Net Profit Growth
2012 -1.654.486
2013 -1.289.456 -28.31%
2014 -5.908.000 78.17%
2015 -22.947.000 74.25%
2016 2.217.000 1135.05%
2017 -49.189.000 104.51%
2018 -41.059.000 -19.8%
2019 -75.788.000 45.82%
2020 -73.430.000 -3.21%
2021 -410.898.000 82.13%
2022 -245.357.000 -67.47%
2023 -96.368.000 -154.6%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Saniona AB (publ) Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 0
2013 0 0%
2014 0 0%
2015 -1 100%
2016 0 0%
2017 -2 100%
2018 -2 -100%
2019 -3 50%
2020 -2 -100%
2021 -7 83.33%
2022 -4 -100%
2023 -2 -200%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Saniona AB (publ) Free Cashflow
Year Free Cashflow Growth
2013 -5.373.000
2014 -8.763.000 38.69%
2015 -29.062.000 69.85%
2016 7.137.000 507.2%
2017 -58.047.000 112.3%
2018 -24.027.000 -141.59%
2019 -101.957.000 76.43%
2020 -179.712.000 43.27%
2021 -346.522.000 48.14%
2022 -282.522.000 -22.65%
2023 -18.692.000 -1411.46%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Saniona AB (publ) Operating Cashflow
Year Operating Cashflow Growth
2013 -3.748.000
2014 -7.958.000 52.9%
2015 -28.820.000 72.39%
2016 7.953.000 462.38%
2017 -57.339.000 113.87%
2018 -22.920.000 -150.17%
2019 -98.469.000 76.72%
2020 -174.713.000 43.64%
2021 -345.038.000 49.36%
2022 -281.537.000 -22.56%
2023 -18.609.000 -1412.91%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Saniona AB (publ) Capital Expenditure
Year Capital Expenditure Growth
2013 1.625.000
2014 805.000 -101.86%
2015 242.000 -232.64%
2016 816.000 70.34%
2017 708.000 -15.25%
2018 1.107.000 36.04%
2019 3.488.000 68.26%
2020 4.999.000 30.23%
2021 1.484.000 -236.86%
2022 985.000 -50.66%
2023 83.000 -1086.75%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Saniona AB (publ) Equity
Year Equity Growth
2012 -1.541.000
2013 575.000 368%
2014 8.781.000 93.45%
2015 52.943.000 83.41%
2016 54.252.000 2.41%
2017 37.628.000 -44.18%
2018 39.457.000 4.64%
2019 58.437.000 32.48%
2020 603.458.000 90.32%
2021 281.999.000 -113.99%
2022 52.708.000 -435.02%
2023 6.670.000 -690.22%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Saniona AB (publ) Assets
Year Assets Growth
2012 8.019.000
2013 15.071.000 46.79%
2014 15.461.000 2.52%
2015 57.673.000 73.19%
2016 70.769.000 18.51%
2017 48.375.000 -46.29%
2018 83.075.000 41.77%
2019 96.000.000 13.46%
2020 692.181.000 86.13%
2021 440.248.000 -57.23%
2022 153.696.000 -186.44%
2023 94.405.000 -62.8%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Saniona AB (publ) Liabilities
Year Liabilities Growth
2012 9.560.000
2013 14.496.000 34.05%
2014 6.680.000 -117.01%
2015 4.730.000 -41.23%
2016 16.517.000 71.36%
2017 10.747.000 -53.69%
2018 43.618.000 75.36%
2019 37.563.000 -16.12%
2020 88.723.000 57.66%
2021 158.249.000 43.93%
2022 100.988.000 -56.7%
2023 87.735.000 -15.11%

Saniona AB (publ) Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.23
Net Income per Share
-1.71
Price to Earning Ratio
-1.8x
Price To Sales Ratio
14.34x
POCF Ratio
-2.33
PFCF Ratio
-2.51
Price to Book Ratio
29.21
EV to Sales
11
EV Over EBITDA
-1.96
EV to Operating CashFlow
-1.94
EV to FreeCashFlow
-1.93
Earnings Yield
-0.55
FreeCashFlow Yield
-0.4
Market Cap
0,21 Bil.
Enterprise Value
0,16 Bil.
Graham Number
2.01
Graham NetNet
-0.61

Income Statement Metrics

Net Income per Share
-1.71
Income Quality
0.72
ROE
-3.95
Return On Assets
-1.49
Return On Capital Employed
-1.71
Net Income per EBT
0.93
EBT Per Ebit
1.29
Ebit per Revenue
-4.73
Effective Tax Rate
0.07

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
-0.63
Operating Profit Margin
-4.73
Pretax Profit Margin
-6.11
Net Profit Margin
-5.69

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-1.32
Free CashFlow per Share
-1.33
Capex to Operating CashFlow
0.01
Capex to Revenue
-0.05
Capex to Depreciation
0
Return on Invested Capital
-11.62
Return on Tangible Assets
-1.24
Days Sales Outstanding
0
Days Payables Outstanding
1078.62
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0.34
Inventory Turnover
0
Capex per Share
-0.01

Balance Sheet

Cash per Share
0,78
Book Value per Share
0,11
Tangible Book Value per Share
0.11
Shareholders Equity per Share
0.11
Interest Debt per Share
0.24
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0.59
Current Ratio
2.77
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
-0,02 Bil.
Invested Capital
0
Working Capital
0,04 Bil.
Intangibles to Total Assets
0.07
Average Receivables
0,00 Bil.
Average Payables
0,01 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Saniona AB (publ) Dividends
Year Dividends Growth

Saniona AB (publ) Profile

About Saniona AB (publ)

Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity. It also develops SAN711, which is in Phase 1 clinical stage for rare neuropathic disorders; SAN903 that is in preclinical stage for rare inflammatory, fibrotic, and hematological disorders. The company has research and collaboration agreements with Boehringer Ingelheim International GmbH; license agreement with Productos Medix, S.A. de C.V.; research services agreement and a collaboration agreement with Cephagenix ApS. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.

CEO
Mr. Jorgen Drejer Ph.D.
Employee
23
Address
Smedeland 26B
Glostrup, 2600

Saniona AB (publ) Executives & BODs

Saniona AB (publ) Executives & BODs
# Name Age
1 Ms. Anita Milland B.Com.
Chief Financial Officer
70
2 Mr. Janus Schreiber Larsen
Chief Development Officer
70
3 Mr. Karin Sandager Nielsen Ph.D.
Chief Scientific Officer
70
4 Mr. Thomas Feldthus M.Sc., MBA
Co-Founder & Chief Executive Officer
70
5 Mr. Palle Christophersen M.S., Ph.D.
Executive Vice President of Research
70
6 Mr. Jorgen Drejer Ph.D.
Founder, Chairman & Deputy Chief Executive Officer
70

Saniona AB (publ) Competitors

GomSpace Group AB (publ) Logo
GomSpace Group AB (publ)

GOMX.ST

(0.8)
Zealand Pharma A/S Logo
Zealand Pharma A/S

ZEAL.CO

(0.5)
Orphazyme A/S Logo
Orphazyme A/S

ORPHA.CO

(0.5)